Trending Now
Markets in precarious situation heading into volatility
The markets are in a precarious situation right now. We are right off all-time highs and the corona virus is spreading.
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Oncolytics Biotech, Inc. (NASDAQ:ONCY) Commences TNBC Study To Investigate The Use...
Oncolytics Biotech, Inc. (NASDAQ:ONCY) begins TNBC (triple-negative breast cancer) study, which is sponsored by the investigator. New Jersey-based Rutgers Cancer Institute (RCI) will manage...
MAKE IT MODERN
LATEST REVIEWS
Evogene Ltd’s (NASDAQ: EVGN) AgPlenus Ltd., Subsidy Has Announced That It...
Evogene Ltd (NASDAQ: EVGN) subsidy, AgPlenus Ltd., recently announced positive results. The results were announced for a Proof of Concept (POC) testing of a...
MAKE IT MODERN
PERFORMANCE TRAINING
Longeveron Inc. (NASDAQ: LGVN) Announces Orphan Drug Designation Grant For Lomecel-B Drug on HLHS
Longeveron Inc. (NASDAQ: LGVN) has announced that the FDA has granted its Lomecel-B drug for Hypoplastic Left Heart Syndrome treatment an Orphan Drug Designation....
Immunomedics, Inc. (NASDAQ:IMMU) Expands Its Current Clinical Collaboration with Roche to Evaluate Trodelvy
Today, many companies are stepping out of their personalized healthcare strategy to accommodate collaborations. This way, they can advance their research and development efforts....
Pot Stocks Shine as Election Resolves (TLRY, GRWG, NUGS, GTBIF)
While there are some knuckle-whitening formalities to traverse, the election appears to be over, with Biden and Harris now in place as President- and...
Cue Biopharma Inc (NASDAQ:CUE) Advances CUE-101 Dose Escalation Phase 1 Monotherapy Clinical Trial
Cue Biopharma Inc (NASDAQ:CUE) received encouraging results in the cohort 5 and cohort 4 dosing and got clearance from the SRC (Safety Review Committee)....
Sorrento Therapeutics Inc‘s (NASDAQ: SRNE) Subsidiary Scilex Holdings Signs Term Sheet To acquire Ancora...
Sorrento Therapeutics Inc's (NASDAQ: SRNE) almost 100% owned subsidiary Scilex Holding Company has signed a term sheet to purchase privately-held medical tech firm Ancora...
MAKE IT MODERN
